1/30/2024 0 Comments Scribe therapeuticsThe company is backed by leading individual and institutional investors including Andreessen Horowitz. Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. Scribe Therapeutics is a molecular engineering company focused on building best-in-class in vivo therapies to permanently treat the underlying cause of disease. Scribe is also eligible to receive tiered, high single digit to sub-teen royalties. Scribe will receive $15 million upfront and is eligible for more than $400 million in potential development and commercial milestone payments between the two targets of interest. Under the terms of the collaboration, Scribe will work with Biogen to create therapeutics for genetically-driven ALS, with an option to pursue an additional neurological disease target with high, unmet need. “We’re proud to collaborate with Biogen and apply our uniquely customized approaches with the goal of developing new, safe and effective genetic medicines for neurodegenerative disease.” Scribe is building and applying a suite of CRISPR technologies designed for therapeutic use into a single continually evolving and expanding genetic. “Scribe has designed, engineered and tested thousands of evolved CRISPR enzymes to build an advanced platform for creating breakthrough in vivo treatments,” said Benjamin Oakes, CEO and co-founder of Scribe Therapeutics. The company’s first technology, X-Editing (XE), provides greater editing activity, specificity and deliverability than other CRISPR genome editing tools currently available. Scribe Therapeutics scribetx 1/ We’re excited to announce the completion of our 100M Series B financing to further develop our CRISPR by Design platform and pipeline of CRISPR-based in vivo genetic medicines that treat the underlying cause of disease. Scribe’s platform is focused on engineering, delivering, and developing novel, custom CRISPR molecules. (Nasdaq:BIIB) to develop and commercialize CRISPR-based therapies that address an underlying genetic cause of Amyotrophic Lateral Sclerosis (ALS). “With molecular engineering at our core, we aim to move beyond discovery towards scalable biological design that can precisely address previously intractable genetic maladies,” he added.Committed to expanding treatment for underserved genetic conditions, Scribe and Biogen to collaborate on the development of novel genetic medicines for neurodegenerationĪLAMEDA, CA, USA I OctoI Scribe Therapeutics Inc., the company focused on engineering the most advanced platform for CRISPR-based genetic medicine, today announced a research collaboration with Biogen Inc. “We are building a future where treating the underlying causes of disease will be achieved by best-in-class, custom engineered technologies,” said Benjamin Oakes, chief executive officer and co-founder of Scribe Therapeutics. Scribe is also exploring additional therapeutic targets, as well as new partnership opportunities, the company said in a statement. The company is already conducting a $400m research collaboration with Biogen to develop CRISPR-based therapies for Amyotrophic Lateral Sclerosis (ALS). ALAMEDA, Calif.- ( BUSINESS WIRE )- Scribe Therapeutics Inc. It is also looking to engineer additional technologies as part of its expanding platform while developing its pipeline to target areas of unmet need. Scribe has already engineered CRISPR enzymes found in nature into millions of novel variants, which it says have ideal therapeutic attributes to enable ‘highly effective and specific in vivo applications’. “Scribe’s engineering-first philosophy has resulted in a uniquely flexible platform for imagining and creating a new era of CRISPR-based therapies to elevate the standard of care for thousands of patients,” said Jennifer Doudna, co-inventor of CRISPR technology, Nobel Laureate and co-founder of Scribe Therapeutics. Scribe’s technology platform can create custom CRISPR molecules that are specifically designed for therapeutic use within the body, overcoming the limitation of using existing enzymes that may lead to ‘poor editing outcomes’. This technology evolved from the natural defence mechanisms of bacteria and archaea, which use RNA and Cas proteins to target and attack viruses and other foreign bodies. The company’s platform is based on CRISPR technology (also known as CRISPR-Cas9) – CRISPRs are specialised stretches of DNA that can be cut by Cas9 enzymes. Scribe Therapeutics, focused on the engineering, delivery, and development of next-generation crispr molecules to rewrite and repair the underlying cause of. Scribe was co-founded by Jennifer Doudna, a co-inventor of CRISPR technology and co-recipient of the 2020 Nobel Prize in Chemistry. Scribe Therapeutics has completed an oversubscribed $100m Series B financing round to advance the development of its CRISPR platform and pipeline.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |